Tandem Diabetes (TNDM) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY24 Revenue Guidance

Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $244 million versus the consensus estimate of $223.66 million.

GUIDANCE:

Tandem Diabetes sees FY2024 revenue of $903-910 million, versus the consensus of $891 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Wolfe Research Upgrades Target (TGT) to Outperform
• Gyre Therapeutics (GYRE) files for 30.22M share offering by selling stockholders